Government Exercises Extraordinary Powers to Limit Trade Margins
In a major intervention aimed at making life-saving oncology care accessible, the National Pharmaceutical Pricing Authority (NPPA) issued an official gazette notification invoking Paragraph 19 of the Drugs (Prices Control) Order, 2013 (DPCO) to enforce Trade Margin Rationalisation (TMR) across 137 non-scheduled anti-cancer formulations.
The regulatory order caps the total trade margin—the spread between the Price to Stockist (PTS) charged by manufacturers and the Maximum Retail Price (MRP) paid by patients—at a maximum of 30 percent. Recommended by an expert committee under the Directorate General of Health Services (DGHS), the measure targets distorted markups where retail chemists and institutional hospitals were pocketing margins exceeding several hundred percent.
Overview: Key Structural Parameters of the Anti-Cancer TMR Order
| Policy & Regulatory Parameter | Official Statutory Specifications |
| Regulatory Body | National Pharmaceutical Pricing Authority (NPPA) |
| Statutory Provision | Paragraph 19, Drugs (Prices Control) Order, 2013 (Public Interest) |
| Trade Margin Cap | 30% of Maximum Retail Price (MRP) (Excluding GST) |
| Scope of Coverage | 137 anti-cancer formulations (~1,000+ brand variations) |
| Expected Price Reduction | Up to 70% reduction in retail prices |
| Estimated Annual Patient Savings | ₹2,500 Crore nationwide |
| Effective Implementation Date | November 9, 2026 |
Broad Spectrum Coverage Across Critical Therapies
The notification covers advanced immunotherapies, targeted targeted small-molecule inhibitors, monoclonal antibodies, and supportive care biologics used across more than 20 distinct cancer types. Key medicines brought under the 30 percent margin ceiling include:
Targeted Immunotherapies: Pembrolizumab, Durvalumab, and Nivolumab.
Organ-Specific Onco-therapeutics: Osimertinib (lung cancer), Bevacizumab (colon, ovarian, cervical cancer), and Denosumab (breast/prostate bone metastases).
Supportive Care Formulations: Pegfilgrastim, used to prevent severe neutropenia and infections during chemotherapy.
By capping the distribution markup without forcing manufacturers to cut ex-factory production prices, the policy safeguards manufacturing revenues and prevents supply disruptions or artificial shortages of essential biologics.
"This exercise curbs excessive trade margins extracted across distribution and hospital retail channels while preserving legitimate manufacturing incentives, ensuring that patients receive immediate relief on out-of-pocket healthcare costs." — National Pharmaceutical Pricing Authority Statement
Mandatory Compliance Timelines and Digital Enforcement
Under the compliance framework, all pharmaceutical manufacturers producing any of the 137 notified formulations must submit their revised PTS and MRP structure to the NPPA within seven days. Updated price lists must be prominently published on company websites and transmitted directly to distributors, chemists, and hospital procurement units.
From November 9, 2026, all retail outlets, hospital pharmacies, and medical institutions are legally bound to bill patients strictly according to the revised lower MRPs. State Drug Controllers have been instructed to execute spot audits, while consumers can cross-verify medicine prices in real time using the government's Pharma Sahi Daam mobile app and official NPPA web portal.
